Naveed Mahfooz, MD
Internal Medicine · Caro, MINPI 1780639450
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,095 of the $12,636 with a category attached, or 87.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Amgen$1K
- Merck$944
- AbbVie$741
- AstraZeneca$682
- Otsuka America Pharmaceutical, Inc.$575
- plus $7K from 54 others
Across 200 payments — averaging $3677.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$276K
- Pfizer$135K
- Esperion Therapeutics, Inc.$83K
- GSK$74K
- Bristol Myers Squibb$65K
- Avanir Pharmaceuticals, Inc.$23K
- plus $79K from 6 others
What the payments were for
- Travel & lodging$1,50112%
- Food & beverage$11,09588%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,636 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,643 | $518,387 |
| TrulicityDulaglutide | 357 | $370,843 |
| JardianceEmpagliflozin | 612 | $281,796 |
| MounjaroTirzepatide | 115 | $149,947 |
| NuplazidPimavanserin Tartrate | 101 | $139,572 |
| OzempicSemaglutide | 109 | $136,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $103,207 |
| JanuviaSitagliptin Phosphate | 144 | $98,206 |
| XareltoRivaroxaban | 323 | $96,373 |
| RexultiBrexpiprazole | 129 | $94,400 |
| LinzessLinaclotide | 152 | $77,242 |
| FarxigaDapagliflozin Propanediol | 174 | $53,820 |
| MyrbetriqMirabegron | 221 | $42,367 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $38,878 |
| EntrestoSacubitril/Valsartan | 80 | $38,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $493 | $520,790472 claims |
| PfizerEliquis | $490 | $518,3871,643 claims |
| Boehringer IngelheimJardiance | $390 | $281,796612 claims |
| Novo NordiskOzempic, Rybelsus | $483 | $173,732159 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,765 | $142,788221 claims |
| Acadia Pharmaceuticals IncNuplazid | $121 | $139,572101 claims |
| MerckJanuvia, Verquvo | $944 | $136,494176 claims |
| Johnson & JohnsonXarelto, Invokana | $269 | $127,489346 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $682 | $112,126282 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $575 | $94,400129 claims |
| AbbVieLinzess | $741 | $77,242152 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $42,367221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Caro
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.